tPA Archives

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

by emottawa | Jan 29, 2013 | Journal Club

Journal Club Summary Methodology: 2.5/5 Usefulness: 2.5/5 IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. Lancet. 2012 Jun 23;379(9834):2352-63. Article Link This international, multicenter, randomized, open-treatment trial was aimed at detecting...

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

by EMOttawa | Jul 9, 2012 | Journal Club, landmark

Journal Club Summary Methodology: 4/5 Usefulness: 4.5/5 Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen...

Next Entries »

Mission Statement

World-Class Emergency Medicine: To provide outstanding compassionate emergency care through practice-changing research and innovative medical education. For more about our department, visit us at EMOttawa.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Mission Statement

Categories

Mission Statement

Categories

Archives